Aortic stenosis Medical Services in China

Aortic stenosis is a progressive valvular heart disease characterized by narrowing of the aortic valve orifice, impeding blood flow from the left ventricle to the aorta. It commonly arises from ageital bicuspid aortic valve, or rheumatic heart disease. As stenosis advances, patients may develop exertional dyspnea, angina, syncope, and ultimately heart failure or sudden cardiac death. Diagnosis relies on echocardiography—particularly transthoracic Doppler ultrasound—to quantify peak velocity, mean pressure gradient, and calculated aortic valve area. Severe symptomatic aortic stenosis warrants intervention: surgical aortic valve replacement (SAVR) remains standard for eligible patients, while transcatheter aortic valve implantation (TAVI) offers a minimally invasive alternative for high- or intermediate and timely intervention significantly improve survival and quality of life.

China offers compelling advantages for international patients seeking treatment. The country hosts numerous nationally accredited cardiovascular centers with extensive experience in both SAVR and TAVI—many performing over 1, annually. Leading hospitals utilize state-of-the-art imaging (3D echocardiography, CT angiography), robotic-assisted surgery platforms, and next-generation transcatheter valves approved by NMPA and CE. Clinical outcomes align with international benchmarks: 30-day consistently below 3%, and five-year survival exceeds 85% in matched cohorts. Crucially, costs are typically 40–60% lower than in the US or Western Europe—without compromising procedural standards or postoperative care. As a dedicated medical tourism agency, we facilitate seamless access to these resources: verifying hospital credentials, coordinating pre-arrival diagnostics, arranging bilingual clinical consultations, providing transparent all-inclusive pricing, and offering end-to-end support follow-up.

Treatment Options & Itemized Cost Breakdown: Aortic Stenosis (Cardiovascular Department)

Non-Surgical / Conservative Management

*Indicated for asymptomatic mild-to-moderate AS or patients unfit for intervention.*

• •Monitoring & Lifestyle Guidance: Annual echocardiogram + clinical assessment

- ECG + Chest X-ray: $35–$50 - NT-proBNP + Lipid Panel + Renal Function (Cr, eGFR): $65–$95

• •Medication Support (symptom control only; *no disease-modifying drugs*):

• •*No pharmacotherapy reverses stenosis or improves survival in severe AS.*

Surgical & Interventional Options

*Eligibility requires confirmed severe AS (aortic valve area ≤1.0 cm², mean gradient ≥40 mmHg, peak velocity ≥4.0 m/s) + symptoms or high-risk features.*

• •Surgical Aortic Valve Replacement (SAVR)

- Procedure (mechanical/bioprosthetic valve): $14,500–$22,000 - Pre-op workup (TTE, TEE, coronary angiography, pulmonary function, CT aortogram): $2,100–$3,300

• •Transcatheter Aortic Valve Implantation (TAVI/TAVR)

- Procedure (self-expanding or balloon-expandable valve): $28,000–$41,000 - Pre-op workup (CT angiography mandatory + TTE/TEE + vascular ultrasound): $2,400–$3,600

Special/Complex Condition Options

• •Low-Flow, Low-Gradient Severe AS with Reduced LVEF: Dobutamine stress echo + advanced hemodynamics → SAVR preferred if contractile reserve present: + $420 (stress echo fee)
• •Bicuspid Aortic Valve with Ascending Aorta >4.5 cm: Combined aortic root replacement + AVR → adds $8,500–$12,000 to SAVR cost
• •Concomitant Coronary Artery Disease: SAVR + CABG → adds $4,800–$7,200

Quick Selection Guide

• •<75 years, low surgical risk, no frailty: SAVR — optimal durability, lowest long-term cost ($16,600–$25,300 total)
• •≥75 years or high surgical risk (e.g., COPD, prior sternotomy, porcelain aorta): TAVI — superior safety, faster recovery ($30,400–$44,600 total)
• •Asymptomatic severe AS with rapid progression (ΔAVA <0.1 cm²/year): Accelerated monitoring (q6mo TTE + BNP) — $240–$360/year, defer intervention until symptom onset
• •Severe AS + end-stage renal disease on dialysis: TAVI via transcarotid/transapical route — $33,000–$46,000, requires multidisciplinary nephrology-cardiology coordination
• •Budget-constrained (<$20,000): SAVR remains only evidence-based curative option; conservative management is *not* cost-effective long-term due to high 2-year mortality (>50%) in symptomatic severe AS.